Section Arrow
OABI.NASDAQ
- OmniAb
Quotes are at least 15-min delayed:2024/11/10 15:44 EST
Last
 4.52
-0.01 (-0.22%)
Day High 
4.63 
Prev. Close
4.53 
1-M High
4.87 
Volume 
310.40K 
Bid
2.8
Ask
5.1
Day Low
4.5 
Open
4.55 
1-M Low
3.72 
Market Cap 
535.28M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.18 
20-SMA 4.09 
50-SMA 4.17 
52-W High 6.715 
52-W Low 3.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.62/-0.28
Enterprise Value
557.35M
Balance Sheet
Book Value Per Share
2.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
34.16M
Operating Revenue Per Share
0.56
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.0189+0.001+5.59%-- 
IOVAIovance Biotherapeutics10.585-1.695-13.80%-- 
SGMOSangamo Therapeutics2.87+0.06+2.14%-- 
ARDXArdelyx5.07-1.31-20.53%-- 
MRNAModerna46.84-3.44-6.84%-- 
Quotes are at least 15-min delayed:2024/11/10 15:44 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable theefficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.